Nomura Asset Management Co. Ltd. Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Nomura Asset Management Co. Ltd. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,923 shares of the biopharmaceutical company’s stock after buying an additional 1,439 shares during the period. Nomura Asset Management Co. Ltd. owned 0.05% of Regeneron Pharmaceuticals worth $51,751,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $26,000. Fortitude Family Office LLC purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $31,000. MCF Advisors LLC increased its position in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares during the period. Criterion Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $37,000. Finally, Bruce G. Allen Investments LLC purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $40,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Leonard S. Schleifer sold 22,830 shares of the business’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the sale, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,925 shares of company stock valued at $53,649,186. 8.83% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $4.45 during trading on Friday, reaching $985.02. 259,279 shares of the company’s stock were exchanged, compared to its average volume of 437,413. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The stock has a market capitalization of $108.54 billion, a P/E ratio of 29.10, a price-to-earnings-growth ratio of 2.02 and a beta of 0.17. The company’s fifty day simple moving average is $944.81 and its 200-day simple moving average is $914.87.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

REGN has been the topic of a number of research reports. Bank of America raised their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price on the stock. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $989.36.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.